WHAT IS CLAIMED:

1. A method of treating a patient having a solid tumor comprising co-administering to the patient a therapeutically effective amount of Compound A (mirdametinib), or a pharmaceutically acceptable salt form thereof, and a therapeutically effective amount of Compound B (lifirafenib), or a pharmaceutically acceptable salt form thereof.

2. The method of claim 1, wherein the therapeutically effective amount of Compound A is about 1 mg to about 5 mg per day.

3. The method of claim 1, wherein the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg to about 40 mg per day.

4. The method of claim 1, wherein the therapeutically effective amount of Compound A is about 1 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg to about 15 mg per day.

5. The method of claim 1, wherein the therapeutically effective amount of Compound A is about 2 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg to about 40 mg per day.

6. The method of claim 1, wherein the therapeutically effective amount of Compound A is about 2 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 20 mg to about 35 mg per day.

7. The method of claim 1, wherein the therapeutically effective amount of Compound A is about 3 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg to about 40 mg per day.

8. The method of claim 1, wherein the therapeutically effective amount of Compound A is about 3 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 20 mg to about 35 mg per day.

9. The method of claim 1, wherein the therapeutically effective amount of Compound A is about 4 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 10 mg to about 40 mg per day.

10. The method of claim 1, wherein the therapeutically effective amount of Compound A is about 4 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 20 mg to about 35 mg per day.

11. The method of claim 1, wherein the therapeutically effective amount of Compound A is about 5 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 10 mg to about 40 mg per day.

12. The method of claim 1, wherein the therapeutically effective amount of Compound A is about 5 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 20 mg to about 40 mg per day.

13. The method of any one of claims 1-12, wherein Compound B is a pharmaceutically acceptable salt form.

14. The method of claim 13, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

15. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 1 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 5 mg to about 10 mg per day.

16. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 1 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 7 mg per day.

17. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 2 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 10 mg to about 30 mg per day.

18. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 2 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 13 mg per day.

19. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 2 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg per day.

20. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 3 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 15 mg to about 40 mg per day.

21. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 3 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 20 mg per day.

22. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 3 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 34 mg per day.

23. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 4 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 20 mg to about 40 mg per day.

24. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 4 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg per day.

25. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 5 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 25 mg to about 40 mg per day.

26. The method of claim 14, wherein the therapeutically effective amount of Compound A is about 5 mg per day and the therapeutically effective amount of Compound B as a maleate salt is about 34 mg per day.

27. The method of any one of claims 1-26, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in the same or different dosage forms.

28. The method of claim 27, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in the same dosage form.

29. The method of claim 28, wherein the dosage form is a capsule.

30. The method of any one of claims 1-29, wherein Compound A is administered once per day.

31. The method of any one of claims 1-30, wherein Compound B, or a pharmaceutically acceptable salt form thereof, is administered once per day.

32. The method of claim 27, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in different dosage forms.

33. The method of claim 32, wherein Compound A is administered before, concomitantly, or subsequently to the administering of Compound B, or a pharmaceutically acceptable salt form thereof.

34. The method of claim 27 or claim 28, wherein the dosage form of Compound A is a capsule.

35. The method of any one of claims 27-34, wherein the dosage form of Compound B, or a pharmaceutically acceptable salt form thereof, is a capsule.

36. The method of any one of claims 1-35, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered orally.

37. The method of any one of claims 1-36, wherein the solid tumor is selected from the group consisting of malignant peripheral nerve sheath tumor, biliary tract cancer, breast cancer, cholangiocarcinoma, urothelial cancer, uterine neoplasm, lung adenocarcinoma, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, gastric cancer, sarcoma, bladder cancer, head and neck cancer, small cell lung cancer, endometrial cancer, esophageal cancer, adenoid cystic carcinoma, gallbladder cancer, colorectal cancer, thyroid cancer, hepatocellular cancer, prostate cancer, oral cancer, cervical cancer, pancreatic carcinoma, ovarian cancer, melanoma, and serous carcinoma to the peritoneum.

38. The method of claim 37, wherein the patient has non-small cell lung cancer.

39. The method of claim 37, wherein the patient has endometrial cancer.

40. The method of claim 37, wherein the patient has ovarian cancer.

41. The method of claim 40, where the patient has low grade serous ovarian cancer.

42. The method of any one of claims 1-41, wherein the patient has a confirmed mutation in one or more of KRAS, NRAS, HRAS, BRAF, NF1, MEK1, and MEK2.

43. The method of any one of claims 1-42, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising: (a) 21 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both administered; and (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

44. The method of any one of claims 1-42, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising (a) 21 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof are both administered; followed by (b) 7 days in which

neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

45. The method of any one of claims 1-42, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 5 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both administered and (ii) 2 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof are administered; and (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

46. The method of any one of claims 1-42, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 5 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both administered and (ii) 2 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered; followed by (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

47. The method of any one of claims 1-42, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 4 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both administered and (ii) 3 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof are administered; and (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

48. The method of any one of claims 1-42, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 4 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both administered and (ii) 3 days in which neither Compound A nor Compound B, or a pharmaceutically

acceptable salt form thereof, is administered; followed by (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

49. The method of any one of claims 43-48, wherein the 28-day dosing cycle is repeated up to a total of 24 consecutive 28-day dosing cycles.

50. The method of any one of claims 43-49, wherein only Compound B, or a pharmaceutically acceptable salt form thereof, is administered for a lead-in period prior to a first 28-day dosing cycle.

51. The method of claim 50, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is the same or lower than the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered during the first 28-day dosing cycle.

52. The method of claim 51, wherein the lead-in period begins 21 days before the first 28-day dosing cycle.

53. The method of claim 52, wherein the lead-in period begins 14 days before the first 28-day dosing cycle.

54. The method of claim 52, wherein the lead-in period begins 10 days before the first 28-day dosing cycle.

55. The method of claim 52, wherein the lead-in period begins 7 days before the first 28-day dosing cycle.

56. The method of any one of claims 50-55, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 25 mg per day.

57. The method of any one of claims 50-55, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 20 mg per day.

58. The method of any one of claims 50-55, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 15 mg per day.

59. The method of any one of claims 50-55, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg per day.

60. The method of any one of claims 50-55, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 10 mg per day.

61. The method of any one of claims 50-55, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 15 mg per day.

62. The method of any one of claims 50-55, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 20 mg per day.

63. The method of any one of claims 50-55, wherein the Compound B administered in the lead-in period is a pharmaceutically acceptable salt form.

64. The method of claim 63, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

65. The method of claim 64, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 40 mg per day.

66. The method of claim 64, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 30 mg per day.

67. The method of claim 64, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 25 mg per day.

68. The method of claim 64, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 7 mg per day.

69. The method of claim 64, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 13 mg per day.

70. The method of claim 64, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 20 mg per day.

71. The method of claim 64, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 27 mg per day.

72. The method of any one of claims 50-71, wherein the Compound B, or a pharmaceutically acceptable salt thereof, is administered daily during the lead-in period.

73. The method of any one of claims 50-72, wherein the Compound B, or a pharmaceutically acceptable salt thereof, is administered once daily during the lead-in period.

74. The method of any one of claims 43-49, wherein one or both of Compound A, or a pharmaceutically acceptable salt form thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, is administered for a lead-in period prior to a first 28-day dosing cycle at a lower dose than the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt form thereof, and Compound B, or a pharmaceutically acceptable salt thereof, administered during the first 28-day cycle.

75. The method of claim 74, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is the same as the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered during the first 28-day dosing cycle.

76. The method of claim 74, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is lower than the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered during the first 28-day dosing cycle.

77. The method of any one of claims 74-76, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 1 mg to about 5 mg per day.

78. The method of any one of claims 74-76, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period about 1 mg per day.

79. The method of any one of claims 74-76, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period about 2 mg per day.

80. The method of any one of claims 74-76, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period about 3 mg per day.

81. The method of any one of claims 74-80, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is the same as the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered during the first 28-day dosing cycle.

82. The method of any one of claims 74-80, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is lower than

the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered during the first 28-day dosing cycle.

83. The method of any one of claims 74-80, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 25 mg per day.

84. The method of any one of claims 74-80, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 20 mg per day.

85. The method of any one of claims 74-80, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 15 mg per day.

86. The method of any one of claims 74-80, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg per day.

87. The method of any one of claims 74-80, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 10 mg per day.

88. The method of any one of claims 74-80, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 15 mg per day.

89. The method of any one of claims 74-80, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 20 mg per day.

90. The method of any one of claims 74-89, wherein the Compound B administered in the lead-in period is a pharmaceutically acceptable salt form.

91. The method of claim 90, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

92. The method of claim 91, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 40 mg per day.

93. The method of claim 91, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 30 mg per day.

94. The method of claim 91, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 25 mg per day.

95. The method of claim 91, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 7 mg per day.

96. The method of claim 91, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 13 mg per day.

97. The method of claim 91, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 20 mg per day.

98. The method of claim 91, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 27 mg per day.

99. The method of any one of claims 74-98, wherein the lead-in period begins 21 days before the first 28-day dosing cycle.

100. The method of any one of claims 74-98, wherein the lead-in period begins 14 days before the first 28-day dosing cycle.

101. The method of any one of claims 74-98, wherein the lead-in period begins 10 days before the first 28-day dosing cycle.

102. The method of any one of claims 74-98, wherein the lead-in period begins 7 days before the first 28-day dosing cycle.

103. The method of any one of claims 74-102, wherein the Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt thereof, are each administered daily during the lead-in period.

104. The method of any one of claims 74-102, wherein the Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt thereof, are each administered once daily during the lead-in period.

105. The method of any one of claims 74-104, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in the same or different dosage forms during the lead-in period.

106. The method of claim 105, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in the same dosage form during the lead-in period.

107. The method of claim 106, wherein the dosage form is a capsule.

108. The method of claim 105, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in different dosage forms during the lead-in period.

109. The method of claim 108, wherein Compound A is administered before, concomitantly, or subsequently to the administering of Compound B, or a pharmaceutically acceptable salt form thereof during the lead-in period.

110. The method of claim 108 or claim 109, wherein the dosage form of Compound A, or a pharmaceutically acceptable salt thereof, is a capsule.

111. The method of claim 108 or claim 109, wherein the dosage form of Compound B, or a pharmaceutically acceptable salt form thereof, is a capsule.

112. The method of any one of claims 74-111, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered orally during the lead-in period.

113. The method of any one of claims 1-112, wherein the patient has a confirmed mutation in RASA1 and/or RAF1.

114. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 1 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 20 mg per day.

115. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 2 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 15 mg per day,

116. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 2 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 20 mg per day.

117. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 3 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 20 mg per day.

118. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 2 mg per day and the therapeutically

effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 15 mg per day.

119. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 3 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 20 mg per day.

120. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 3 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 15 mg per day.

121. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 4 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 20 mg per day.

122. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 4 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 15 mg per day.

123. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 4 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg per day.

124. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 4 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 10 mg per day.

125. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 8 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg per day.

126. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 8 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 10 mg per day.

127. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 12 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg per day.

128. The method of claim 1, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 12 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 10 mg per day.

129. The method of any one of claims 114-128, wherein Compound B is a pharmaceutically acceptable salt form.

130. The method of claim 129, wherein the pharmaceutically acceptable salt form is a maleate salt which can be a sesqui-maleate salt.

131. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 1 mg per day and the therapeutically effective amount of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg per day.

132. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 2 mg per day and the

therapeutically effective amount of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 20 mg per day,

133. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 2 mg per day and the therapeutically effective amount of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg per day.

134. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 3 mg per day and the therapeutically effective amount of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg per day.

135. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 2 mg per day and the therapeutically effective amount of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 20 mg per day.

136. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 3 mg per day and the therapeutically effective amount of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg per day.

137. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 3 mg per day and the therapeutically effective amount of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 20 mg per day.

138. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 4 mg per day and the therapeutically effective amount of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg per day.

139. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 4 mg per day and the therapeutically effective amount of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 20 mg per day.

140. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 4 mg per day and the therapeutically effective amount of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 7 mg per day.

141. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 4 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 13 mg per day.

142. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 8 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 7 mg per day.

143. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 8 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 13 mg per day.

144. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 12 mg per day and the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 7 mg per day.

145. The method of claim 130, wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 12 mg per day and the

therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 13 mg per day.

146. The method of any one of claims 114-145, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in the same or different dosage forms.

147. The method of claim 146, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in the same dosage form.

148. The method of claim 147, wherein the dosage form is a capsule.

149. The method of any one of claims 114-148, wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered once per day.

150. The method of any one of claims 114-149, wherein Compound B, or a pharmaceutically acceptable salt form thereof, is administered once per day.

151. The method of claim 146, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in different dosage forms.

152. The method of claim 151, wherein Compound A is administered before, concomitantly, or subsequently to the administering of Compound B, or a pharmaceutically acceptable salt form thereof.

153. The method of claim 151 or claim 152, wherein the dosage form of Compound A, or a pharmaceutically acceptable salt thereof, is a capsule.

154. The method of claim 151 or claim 152, wherein the dosage form of Compound B, or a pharmaceutically acceptable salt form thereof, is a capsule.

155. The method of any one of claims 114-154, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered orally.

156. The method of any one of claims 114-155, wherein the solid tumor is selected from the group consisting of malignant peripheral nerve sheath tumor, biliary tract cancer, breast cancer, cholangiocarcinoma, urothelial cancer, uterine neoplasm, lung adenocarcinoma, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, gastric cancer, sarcoma, bladder cancer, head and neck cancer, small cell lung cancer, endometrial cancer, esophageal cancer, adenoid cystic carcinoma, gallbladder cancer, colorectal cancer, thyroid cancer, hepatocellular cancer, prostate cancer, oral cancer, cervical cancer, pancreatic carcinoma, ovarian cancer, melanoma, and serous carcinoma to the peritoneum.

157. The method of claim 156, wherein the patient has non-small cell lung cancer.

158. The method of claim 156, wherein the patient has endometrial cancer.

159. The method of claim 156, wherein the patient has ovarian cancer.

160. The method of claim 156, where the patient has low grade serous ovarian cancer.

161. The method of any one of claims 114-160, wherein the patient has a confirmed mutation in one or more of KRAS, NRAS, HRAS, BRAF, NF1, MEK1, and MEK2.

162. The method of any one of claims 114-161, wherein the patient has a confirmed mutation in RASA1 and/or RAF1.

163. The method of any one of claims 114-162, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising: (a) 21 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both administered; and (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

164. The method of any one of claims 114-162, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising (a) 21 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof are both administered; followed by (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

165. The method of any one of claims 114-162, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 5 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both administered and (ii) 2 days in which neither Compound A, or a pharmaceutically acceptable salt thereof, nor Compound B, or a pharmaceutically acceptable salt form thereof are administered; and (b) 7 days in which neither Compound A, or a pharmaceutically acceptable salt thereof, nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

166. The method of any one of claims 114-162, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 5 days in which Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are both administered and (ii) 2 days in which neither Compound A, or a pharmaceutically acceptable salt thereof, nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered; followed by (b) 7 days in which neither Compound A, or a pharmaceutically acceptable salt thereof, nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

167. The method of any one of claims 114-162, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 4 days in which Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are both

administered and (ii) 3 days in which neither Compound A, or a pharmaceutically acceptable salt thereof, nor Compound B, or a pharmaceutically acceptable salt form thereof are administered; and (b) 7 days in which neither Compound A, or a pharmaceutically acceptable salt thereof, nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

168. The method of any one of claims 114-162, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 4 days in which Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are both administered and (ii) 3 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered; followed by (b) 7 days in which neither Compound A, or a pharmaceutically acceptable salt thereof, nor Compound B, or a pharmaceutically acceptable salt form thereof, is administered.

169. The method of any one of claims 163-168, wherein the 28-day dosing cycle is repeated up to a total of 24 consecutive 28-day dosing cycles.

170. The method of any one of claims 163-168, wherein only Compound B, or a pharmaceutically acceptable salt form thereof, is administered for a lead-in period prior to a first 28-day dosing cycle.

171. The method of claim 170, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is the same or lower than the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered during the first 28-day dosing cycle.

172. The method of claim 171, wherein the lead-in period begins 21 days before the first 28-day dosing cycle.

173. The method of claim 171, wherein the lead-in period begins 14 days before the first 28-day dosing cycle.

174. The method of claim 171, wherein the lead-in period begins 10 days before the first 28-day dosing cycle.

175. The method of claim 171, wherein the lead-in period begins 7 days before the first 28-day dosing cycle.

176. The method of any one of claims 163-168, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 25 mg per day.

177. The method of any one of claims 163-168, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 20 mg per day.

178. The method of any one of claims 163-168, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 15 mg per day.

179. The method of any one of claims 163-168, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg per day.

180. The method of any one of claims 163-168, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 10 mg per day.

181. The method of any one of claims 163-168, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 15 mg per day.

182. The method of any one of claims 163-168, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 20 mg per day.

183. The method of any one of claims 163-168, wherein the Compound B administered in the lead-in period is a pharmaceutically acceptable salt form.

184. The method of claim 183, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

185. The method of claim 184, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 40 mg per day.

186. The method of claim 184, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 30 mg per day.

187. The method of claim 184, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 25 mg per day.

188. The method of claim 184, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 7 mg per day.

189. The method of claim 184, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 13 mg per day.

190. The method of claim 184, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 20 mg per day.

191. The method of claim 184, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 27 mg per day.

192. The method of any one of claims 170-191, wherein the Compound B, or a pharmaceutically acceptable salt thereof, is administered daily during the lead-in period.

193. The method of any one of claims 170-192, wherein the Compound B, or a pharmaceutically acceptable salt thereof, is administered once daily during the lead-in period.

194. The method of any one of claims 163-168, wherein one or both of Compound A, or a pharmaceutically acceptable salt form thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, is administered for a lead-in period prior to a first 28-day dosing cycle at a lower dose than the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt form thereof, and Compound B, or a pharmaceutically acceptable salt thereof, administered during the first 28-day cycle.

195. The method of claim 194, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is the same as the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered during the first 28-day dosing cycle.

196. The method of claim 194, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is lower than the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered during the first 28-day dosing cycle.

197. The method of any one of claims 194-196, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 1 mg to about 5 mg per day.

198. The method of any one of claims 194-196, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period about 1 mg per day.

199. The method of any one of claims 194-196, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period about 2 mg per day.

200. The method of any one of claims 194-196, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, administered in the lead-in period about 3 mg per day.

201. The method of any one of claims 194-200, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is the same as the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered during the first 28-day dosing cycle.

202. The method of any one of claims 194-200, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is lower than the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered during the first 28-day dosing cycle.

203. The method of any one of claims 194-202, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 25 mg per day.

204. The method of any one of claims 194-202, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 20 mg per day.

205. The method of any one of claims 194-202, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg to about 15 mg per day.

206. The method of any one of claims 194-202, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 5 mg per day.

207. The method of any one of claims 194-202, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 10 mg per day.

208. The method of any one of claims 194-202, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 15 mg per day.

209. The method of any one of claims 194-202, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, administered in the lead-in period is about 20 mg per day.

210. The method of any one of claims 194-209, wherein the Compound B administered in the lead-in period is a pharmaceutically acceptable salt form.

211. The method of claim 210, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

212. The method of claim 211, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 40 mg per day.

213. The method of claim 211, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 30 mg per day.

214. The method of claim 211, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 5 mg to about 25 mg per day.

215. The method of claim 211, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 7 mg per day.

216. The method of claim 211, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 13 mg per day.

217. The method of claim 211, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 20 mg per day.

218. The method of claim 211, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 27 mg per day.

219. The method of any one of claims 194-218, wherein the lead-in period begins 21 days before the first 28-day dosing cycle.

220. The method of any one of claims 194-218, wherein the lead-in period begins 14 days before the first 28-day dosing cycle.

221. The method of any one of claims 194-218, wherein the lead-in period begins 10 days before the first 28-day dosing cycle.

222. The method of any one of claims 194-218, wherein the lead-in period begins 7 days before the first 28-day dosing cycle.

223. The method of any one of claims 194-222, wherein the Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt thereof, are each administered daily during the lead-in period.

224. The method of any one of claims 194-222, wherein the Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt thereof, are each administered once daily during the lead-in period.

225. The method of any one of claims 194-222, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in the same or different dosage forms during the lead-in period.

226. The method of claim 225, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in the same dosage form during the lead-in period.

227. The method of claim 226, wherein the dosage form is a capsule.

228. The method of claim 225, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in different dosage forms during the lead-in period.

229. The method of claim 228, wherein Compound A is administered before, concomitantly, or subsequently to the administering of Compound B, or a pharmaceutically acceptable salt form thereof during the lead-in period.

230. The method of claim 228 or claim 229, wherein the dosage form of Compound A, or a pharmaceutically acceptable salt thereof, is a capsule.

231. The method of claim 228 or claim 229, wherein the dosage form of Compound B, or a pharmaceutically acceptable salt form thereof, is a capsule.

232. The method of any one of claims 194-231, wherein Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, are administered orally during the lead-in period.

233. The method of any one of claims 1-232, wherein Compound A is provided in a pharmaceutically acceptable salt form.

234. The method of any one of claims 1-232, wherein Compound A is provided in free base form.

235. A method of treating a patient having a solid tumor comprising administering once daily 2 mg Compound A as free base and 15 mg Compound B, or a pharmaceutically acceptable salt thereof.

236. The method of claim 235, wherein the Compound B is administered as a pharmaceutically acceptable salt form.

237. The method of claim 236, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

238. The method of claim 237, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 20 mg.

239. A method of treating a patient having a solid tumor comprising administering once daily 2 mg Compound A as free base and 20 mg Compound B, or a pharmaceutically acceptable salt thereof.

240. The method of claim 239, wherein the Compound B is administered as a pharmaceutically acceptable salt form.

241. The method of claim 240, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

242. The method of claim 241, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg.

243. A method of treating a patient having a solid tumor comprising a 7 day cycle that comprises (a) administering once daily 3 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form for 5 consecutive days; followed by (b) administering no Compound A or Compound B for 2 consecutive days.

244. The method of claim 243, wherein the Compound B is administered as a pharmaceutically acceptable salt form.

245. The method of claim 244, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

246. The method of claim 245, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg.

247. A method of treating a patient having a solid tumor comprising:

(a) a lead-in period that comprises administering once daily 3 mg Compound A free base and 10 mg Compound B, or a pharmaceutically acceptable salt form thereof, for 14 consecutive days; followed by

(b) a 7 day treatment cycle that comprises (i) administering once daily 3 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form therefore, for 5 consecutive days; followed by (ii) administering no Compound A or Compound B for 2 consecutive days.

248. The method of claim 247, wherein the Compound B is administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form.

249. The method of claim 248, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

250. The method of claim 249, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 13 mg.

251. The method of claim 250, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the treatment period is about 27 mg.

252. A method of treating a patient having a solid tumor comprising:

(a) a lead-in period that comprises administering a total of 2 mg Compound A free base divided over two doses per day and 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, once daily for 14 consecutive days; followed by

(b) a 7 day treatment cycle that comprises (i) administering 1 mg of Compound A free base twice daily and 15 mg of Compound B, or a pharmaceutically acceptable salt form therefore, once daily for 5 consecutive days; followed by (ii) administering no Compound A or Compound B for 2 consecutive days.

253. The method of claim 252, wherein the Compound B is administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form.

254. The method of claim 253, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

255. The method of claim 254, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 13 mg.

256. The method of claim 255, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the treatment period is about 20 mg.

257. A method of treating a patient having a solid tumor comprising a 7 day cycle that comprises (a) administering once daily 4 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form for 5 consecutive days; followed by (b) administering no Compound A or Compound B for 2 consecutive days.

258. The method of claim 257, wherein the Compound B is administered as a pharmaceutically acceptable salt form.

259. The method of claim 258, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

260. The method of claim 259, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg.

261. A method of treating a patient having a solid tumor comprising:

(a) a lead-in period that comprises administering 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, once daily for 14 consecutive days; followed by

(b) a 7 day treatment cycle that comprises (i) administering once daily 1 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form therefore, once daily for 5 consecutive days; followed by (ii) administering no Compound A or Compound B for 2 consecutive days.

262. The method of claim 261, wherein the Compound B is administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form.

263. The method of claim 262, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

264. The method of claim 263, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 20 mg.

265. The method of claim 264, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the treatment period is about 27 mg.

266. A method of treating a patient having a solid tumor comprising:

(a) a lead-in period that comprises administering 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, once daily for 14 consecutive days; followed by

(b) a 7 day treatment cycle that comprises (i) administering once daily 2 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form therefore, once daily for 5 consecutive days; followed by (ii) administering no Compound A or Compound B for 2 consecutive days.

267. The method of claim 266, wherein the Compound B is administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form.

268. The method of claim 267, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

269. The method of claim 268, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 20 mg.

270. The method of claim 269, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the treatment period is about 27 mg.

271. A method of treating a patient having a solid tumor comprising:

(a) a lead-in period that comprises administering 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, once daily for 14 consecutive days; followed by

(b) a 7 day treatment cycle that comprises (i) administering once daily 3 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form therefore, once daily for 5 consecutive days; followed by (ii) administering no Compound A or Compound B for 2 consecutive days.

272. The method of claim 271, wherein the Compound B is administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form.

273. The method of claim 272, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

274. The method of claim 273, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 20 mg.

275. The method of claim 274, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the treatment period is about 27 mg.

276. A method of treating a patient having a solid tumor comprising:

(a) a lead-in period that comprises administering 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, once daily for 14 consecutive days; followed by

(b) a 7 day treatment cycle that comprises (i) administering once daily 4 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form therefore, once daily for 5 consecutive days; followed by (ii) administering no Compound A or Compound B for 2 consecutive days.

277. The method of claim 276, wherein the Compound B is administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form.

278. The method of claim 277, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

279. The method of claim 278, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 20 mg.

280. The method of claim 279, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the treatment period is about 27 mg.

281. A method of treating a patient having a solid tumor comprising:

(a) a lead-in period that comprises administering a total of 3 mg Compound A free base divided over two doses per day and 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, once daily, for 14 consecutive days; followed by

(b) a 7 day treatment cycle that comprises (i) administering once daily 3 mg of Compound A free base and 15 mg of Compound B, or a pharmaceutically acceptable salt form therefore, for 5 consecutive days; followed by (ii) administering no Compound A or Compound B for 2 consecutive days.

282. The method of claim 281, wherein the Compound B is administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form.

283. The method of claim 282, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

284. The method of claim 283, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 13 mg.

285. The method of claim 284, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the treatment period is about 20 mg.

286. A method of treating a patient having a solid tumor comprising:

(a) a lead-in period that comprises administering a total of 4 mg Compound A free base divided over two doses per day and 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, once daily for 14 consecutive days; followed by

(b) a 7 day treatment cycle that comprises (i) administering once daily 4 mg of Compound A free base and 15 mg of Compound B, or a pharmaceutically acceptable salt form therefore, once daily for 5 consecutive days; followed by (ii) administering no Compound A or Compound B for 2 consecutive days.

287. The method of claim 286, wherein the Compound B is administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form.

288. The method of claim 287, wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

289. The method of claim 288, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the lead-in period is about 13 mg.

290. The method of claim 289, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, administered in the treatment period is about 20 mg.

291. A method of treating a patient having a solid tumor comprising administering twice daily 2 mg Compound A as free base and once daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof.

292. A method of treating a patient having a solid tumor comprising administering twice daily 4 mg Compound A as free base and once daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof.

293. A method of treating a patient having a solid tumor comprising administering twice daily 6 mg Compound A as free base and once daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof.

294. A method of treating a patient having a solid tumor comprising administering twice daily 2 mg Compound A as free base and twice daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof.

295. A method of treating a patient having a solid tumor comprising administering twice daily 4 mg Compound A as free base and twice daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof.

296. A method of treating a patient having a solid tumor comprising administering twice daily 6 mg Compound A as free base and twice daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof.

297. The method of any one of claims 292-296, wherein Compound B is a pharmaceutically acceptable salt form.

298. The method of claim 297, wherein the pharmaceutically acceptable salt form is a maleate salt which can be a sesqui-maleate salt.

299. The method of claim 297, wherein each dose of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 7 mg.

300. The method of any one of claims 235-299, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, in the lead-in period and/or treatment period are administered in the same or different dosage forms.

301. The method of claim 301, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, in the lead-in period and/or treatment period are administered in the same dosage form.

302. The method of claim 302, wherein the dosage form is a capsule.

303. The method of any one of claims 235-300, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, in the lead-in period and/or treatment period are administered in different dosage forms.

304. The method of claim 303, wherein Compound A is administered before, concomitantly, or subsequently to the administering of Compound B, or a pharmaceutically acceptable salt form thereof.

305. The method of claim 303 or claim 304, wherein the dosage form of Compound A is a capsule.

306. The method of any one of claims 303-305, wherein the dosage form of Compound B, or a pharmaceutically acceptable salt form thereof, is a capsule.

307. The method of any one of claims 235-306, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered orally.

308. The method of any one of claims 235-307, wherein the solid tumor is selected from the group consisting of malignant peripheral nerve sheath tumor, biliary tract cancer, breast cancer, cholangiocarcinoma, urothelial cancer, uterine neoplasm, lung adenocarcinoma, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, gastric cancer, sarcoma, bladder cancer, head and neck cancer, small cell lung cancer, endometrial cancer, esophageal cancer, adenoid cystic carcinoma, gallbladder cancer, colorectal cancer, thyroid cancer, hepatocellular cancer, prostate cancer, oral cancer, cervical cancer, pancreatic carcinoma, ovarian cancer, melanoma, and serous carcinoma to the peritoneum.

309. The method of claim 308, wherein the patient has non-small cell lung cancer.

310. The method of claim 308, wherein the patient has endometrial cancer.

311. The method of claim 308, wherein the patient has ovarian cancer.

312. The method of claim 311, where the patient has low grade serous ovarian cancer.

313. The method of any one of claims 235-312, wherein the patient has a confirmed mutation in one or more of KRAS, NRAS, HRAS, BRAF, NF1, MEK1, and MEK2.

314. The method of any one of claims 235-313, wherein the patient has a confirmed mutation in RASA1 and/or RAF1.

315. A pharmaceutical composition comprising:

a. Compound A;
b. Compound B, or a pharmaceutically acceptable salt form thereof;
c. a filler;
d. a disintegrant; and
e. a lubricant.

316. The pharmaceutical composition of claim 315, wherein Compound A is present at about 0.8 mg to about 1.2 mg.

317. The pharmaceutical composition of claim 315, wherein Compound A is present at about 1.5 mg to about 2.5 mg.

318. The pharmaceutical composition of any one of claims 315-317, wherein the pharmaceutically acceptable salt of Compound B is the maleic acid salt, which can be a sesqui-maleate salt, of Compound B and is present at about 6 mg to about 8 mg.

319. The pharmaceutical composition of any one of claims 315-317, wherein the pharmaceutically acceptable salt of Compound B is the maleic acid salt, which can be a sesqui-maleate salt, of Compound B and is present at about 20 mg to about 35 mg.

320. The pharmaceutical composition of any one of claims 315-319, wherein the filler is present at about 80 wt/wt % to about 90 wt/wt %.

321. The pharmaceutical composition of any one of claims 315-319, wherein the filler is present at about 72.5 wt/wt % to about 85 wt/wt %.

322. The pharmaceutical composition of any one of claims 315-321, wherein the disintegrant is present at about 3.5 wt/wt % to about 4.5 wt/wt %.

323. The pharmaceutical composition of any one of claims 315-322, wherein the lubricant is present at about 1.5 wt/wt % to about 5.0 wt/wt %.

324. The pharmaceutical composition of any one of claims 315-323, wherein the filler is selected from the group consisting of microcrystalline cellulose, lactose, mannitol, starch, dibasic calcium phosphate, and combinations thereof.

325. The pharmaceutical composition of claim 324, wherein the filler comprises microcrystalline cellulose.

326. The pharmaceutical composition of claim 325, wherein the microcrystalline cellulose is silicified microcrystalline cellulose.

327. The pharmaceutical composition of any one of claims 315-326, wherein the disintegrant is selected from the group consisting of croscarmellose, sodium starch glycolate, crospovidone, alginic acid, and combinations thereof.

328. The pharmaceutical composition of claim 327, wherein the disintegrant comprises croscarmellose sodium.

329. The pharmaceutical composition of any one of claims 315-328, wherein the lubricant is selected from the group consisting of sodium stearyl fumarate, magnesium stearate, glyceryl dibehenate, talc, or combinations thereof.

330. The pharmaceutical composition of claim 329, wherein the lubricant comprises sodium stearyl fumarate

331. The pharmaceutical composition of claim 329, wherein the lubricant comprises magnesium stearate.

332. The pharmaceutical composition of any one of claims 315-331, wherein the pharmaceutically acceptable salt of Compound B is the maleic acid salt of Compound B, which can be a sesqui-maleate salt.

333. The pharmaceutical composition of any one of claims 315-332, wherein the pharmaceutical composition is a tablet or capsule.

334. The pharmaceutical composition of claim 333, wherein the pharmaceutical composition is a capsule.

335. The pharmaceutical composition of claim 334, wherein the capsule comprises about 1.0 mg of Compound A and about 7 mg of the maleic acid salt of Compound B, which can be a sesqui-maleate salt, wherein each component of the capsule is as follows:

a. about 0.8 wt/wt % to about 1.2 wt/wt % of Compound A;

b. about 6 wt/wt % to about 8 wt/wt % of the maleic acid salt of Compound B, which can be a sesqui-maleate salt;

c. about 80 wt/wt % to about 90 wt/wt % of silicified microcrystalline cellulose;

d. about 3.5 wt/wt % to about 4.5 wt/wt % of croscarmellose sodium;

e. about 1.5 wt/wt % to about 5.0 wt/wt % of sodium stearyl fumarate; and

f. a gelatin capsule which encapsulates components a-e.

336. The pharmaceutical composition of any claim 334, wherein the capsule comprises about 2.0 mg of Compound A and about 27 mg of the maleic acid salt, which can be a sesqui-maleate salt, of Compound B, wherein each component of the capsule is as follows:

a. about 0.8 wt/wt % to about 1.3 wt/wt % of Compound A;

b. about 12.3 wt/wt % to about 15.0 wt/wt % of the maleic acid salt of Compound B, which can be a sesqui-maleate salt;

c. about 72.5 wt/wt % to about 85 wt/wt % of silicified microcrystalline cellulose;

d. about 3.5 wt/wt % to about 4.5 wt/wt % of croscarmellose sodium;

e. about 1.5 wt/wt % to about 5.0 wt/wt % of sodium stearyl fumarate; and

f. a gelatin capsule which encapsulates components a-e.

337. A method of treating a patient having a solid tumor comprising administering to the patient in need thereof, a pharmaceutical composition of any one of claims 315-336.

338. The method of claim 337, wherein the solid tumor is selected from the group consisting of malignant peripheral nerve sheath tumor, biliary tract cancer, breast cancer, cholangiocarcinoma, urothelial cancer, uterine neoplasm, lung adenocarcinoma, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, gastric cancer, sarcoma, bladder cancer, head and neck cancer, small cell lung cancer, endometrial cancer, esophageal cancer, adenoid cystic carcinoma, gallbladder cancer, colorectal cancer, thyroid cancer, hepatocellular cancer, prostate cancer, oral cancer, cervical cancer, pancreatic carcinoma, ovarian cancer, melanoma, and serous carcinoma to the peritoneum.

339. The method of claim 338, wherein the patient has non-small cell lung cancer.

340. The method of claim 338, wherein the patient has endometrial cancer.

341. The method of claim 338, wherein the patient has ovarian cancer.

342. The method of claim 341, where the patient has low grade serous ovarian cancer.

343. The method of any one of claims 338-342, wherein the patient has a confirmed mutation in one or more of KRAS, NRAS, HRAS, BRAF, NF1, MEK1, and MEK2.

344. The method of any one of claims 338-343, wherein the pharmaceutical composition of any one of claims 315-335 is administered on a 28-day dosing cycle comprising: (a) 21 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof form, is administered; and (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not administered.

345. The method of any one of claims 338-343, wherein the pharmaceutical composition of any one of claims 315-335 is administered on a 28-day dosing cycle comprising (a) 21 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is administered; followed by (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not administered.

346. The method of any one of claims 338-343, wherein the pharmaceutical composition of any one of claims 315-335 is administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 5 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is administered and (ii) 2 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not administered; and (b) 7 days in which the pharmaceutical composition

comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not administered.

347. The method of any one of claims 338-344, wherein the pharmaceutical composition of any one of claims 315-335 is administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 5 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is administered and (ii) 2 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not administered; followed by (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not administered.

348. The method of any one of claims 338-343, wherein the pharmaceutical composition of any one of claims 315-335 is administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 4 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is administered and (ii) 3 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is administered; and (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not administered.

349. The method of any one of claims 338-343, wherein the pharmaceutical composition of any one of claims 315-335 is administered on a 28-day dosing cycle comprising (a) three 7-day periods each comprising (i) 4 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is administered and (ii) 3 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not administered; followed by (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not administered.

350. The method of any one of claims 334-349, wherein the 28-day dosing cycle is repeated up to a total of 24 consecutive 28-day dosing cycles.

351. The method of any one of claims 338-343, wherein the pharmaceutical composition of any one of claims 315-335 is administered on a 7-day dosing cycle comprising (a) 5 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is administered; followed by (b) 2 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not administered.

352. The method of any one of claims 338-351, wherein the patient has a confirmed mutation in RASA1 and/or RAF1.

353. Use of a combination of Compound A, or a pharmaceutically acceptable salt form thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, for the manufacture of a medicament for treating a patient having a solid tumor.

354. The use of claim 353, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are in the same or different dosage forms.

355. The use of claim 354, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are in the same dosage form.

356. The use of claim 355, wherein the dosage form is the pharmaceutical composition of any one of claims 315-350.

357. The use of claim 354, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered in different dosage forms.

358. The use of claim 357, wherein Compound A is administered before, concomitantly, or subsequently to the administering of Compound B, or a pharmaceutically acceptable salt form thereof.

359. The use of claim 357 or claim 358, wherein the dosage form of Compound A is a capsule.

360. The use of any one of claims 357-359, wherein the dosage form of Compound B, or a pharmaceutically acceptable salt form thereof, is a capsule.

361. The use of any one of claims 357-359, wherein the pharmaceutically acceptable salt of Compound B is the maleic acid salt of Compound B.

362. The use of any one of claims 357-360, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are administered orally.

363. The use of any one of claims 353-360, wherein the solid tumor is selected from the group consisting of malignant peripheral nerve sheath tumor, biliary tract cancer, breast cancer, cholangiocarcinoma, urothelial cancer, uterine neoplasm, lung adenocarcinoma, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, gastric cancer, sarcoma, bladder cancer, head and neck cancer, small cell lung cancer, endometrial cancer, esophageal cancer, adenoid cystic carcinoma, gallbladder cancer, colorectal cancer, thyroid cancer, hepatocellular cancer, prostate cancer, oral cancer, cervical cancer, pancreatic carcinoma, ovarian cancer, melanoma, and serous carcinoma to the peritoneum.

364. The use of claim 363, wherein the patient has non-small cell lung cancer.

365. The use of claim 363, wherein the patient has endometrial cancer.

366. The use of claim 363, wherein the patient has ovarian cancer.

367. The use of claim 366, where the patient has low grade serous ovarian cancer.

368. The use of any one of claims 353-367, wherein the patient has a confirmed mutation in one or more of KRAS, NRAS, HRAS, BRAF, NF1, MEK1, and MEK2.

369. The use of any one of claims 353-367, wherein the patient has a confirmed mutation in RASA1 and/or RAF1.